Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section

American Journal of Clinical Pathology

Volumn 137, Issue 1, 2012, Pages 102-110

  Reisenbichler, Emily S ^a   Horton, Debra ^a   Rasco, Marva ^a   Andea, Aleodor ^a,b   Hameed, Omar ^a,b,c,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Kentucky   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; Chromogenic in situ hybridization; HER2; Immunohistochemistry; Validation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CARCINOMA; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL PROTOCOL; ECONOMIC ASPECT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TISSUE SECTION; VALIDATION STUDY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2;

EID: 84855266762     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPLNHINN9O6YSF     Document Type: Article

References (26)

1. Minot DM, Kipp BR, Root RM, et al. Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH. Am J Clin Pathol. 2009;132:133-138.
2. Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009;132:539-548.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182. (Pubitemid 17231334)
4. Mayr D, Heim S, Weyrauch K, et al. Chromogenic in situ hybridization for HER-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology. 2009;55:716-723.
5. Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol. 2009;131:490-497.
6. Gong Y, Sweet W, Duh YJ, et al. Performance of chromogenic in situ hybridization on testing HER2 status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) HercepTest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol. 2009;132:228-236.
7. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
8. Hameed O, Chhieng DC, Adams AL. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma? Am J Clin Pathol. 2007;128:825-829. (Pubitemid 350133995)
9. Hameed O, Adams AL, Baker AC, et al. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. Am J Clin Pathol. 2008;130:425-427.
10. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972-1977. (Pubitemid 38544278)
11. Hutchens KA, Lapetino S, Brown H. Less is more: repeat HER-2/neu testing and universal implementation of fluorescence in situ hybridization [abstract]. Am J Clin Pathol. 2009;132:623.
12. Downs-Kelly E, Pettay J, Hicks D, et al. Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol. 2005;29:1505-1511. (Pubitemid 41513301)
13. Ni R, Mulligan AM, Have C, et al. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/ neu) status in breast cancer. Appl Immunohistochem Mol Morphol. 2007;15:316-324. (Pubitemid 47329925)
14. Hameed O, Sublett J, Humphrey PA. Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol. 2005;29:579-587. (Pubitemid 40577866)
15. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777. (Pubitemid 24173773)
16. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323- 1333.
17. Francz M, Egervari K, Kardos L, et al. Comparison of PathVysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study. J Clin Pathol. 2010;63:341-346.
18. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol. 2007;38:1105-1122. (Pubitemid 47058171)
19. Nakhleh RE, Grimm EE, Idowu MO, et al. Laboratory compliance with the American Society of Clinical Oncology/ College of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med. 2010;134:728-734.
20. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133:611-612.
21. Chiu KP, Duca KA, Berman SA, et al. A novel in situ double-labeling method for simultaneous detection of mRNA and expressed protein or two different mRNAs. J Neurosci Methods. 1996;66:69-79. (Pubitemid 26244698)
22. Pineau I, Barrette B, Vallieres N, et al. A novel method for multiple labeling combining in situ hybridization with immunofluorescence. J Histochem Cytochem. 2006;54:1303-1313. (Pubitemid 44623350)
23. Shivers BD, Harlan RE, Pfaff DW, et al. Combination of immunocytochemistry and in situ hybridization in the same tissue section of rat pituitary. J Histochem Cytochem. 1986;34:39-43. (Pubitemid 16175844)
24. Steel JH, O'Halloran DJ, Jones PM, et al. Combined use of immunocytochemistry and in situ hybridization to study beta thyroid-stimulating hormone gene expression in pituitaries of hypothyroid rats. Mol Cell Probes. 1990;4:385-396.
25. Wahle P, Beckh S. A method of in situ hybridization combined with immunocytochemistry, histochemistry, and tract tracing to characterize the mRNA expressing cell types in heterogeneous neuronal populations. J Neurosci Methods. 1992;41:153-166.
26. Otali D, Stockard CR, Oelschlager DK, et al. Combined effects of formalin fixation and tissue processing on immunorecognition. Biotech Histochem. 2009;84:223-247.